title: Exploring gene-environment interactions in Parkinson's disease.
abstract: The objective of this study was to explore combined effects of four candidate susceptibility genes and two exposures on Parkinson's disease (PD) risk; namely, alpha-synuclein (SNCA) promoter polymorphism REP1, microtubule-associated protein tau (MAPT) H1/H2 haplotypes, apolipoprotein E (APOE) epsilon2/epsilon3/epsilon4 polymorphism, ubiquitin carboxy-terminal esterase L1 (UCHL1) S18Y variant, cigarette smoking and caffeinated coffee consumption. 932 PD patients and 664 control subjects from the NeuroGenetics Research Consortium, with complete data on all six factors, were studied. Uniform protocols were used for diagnosis, recruitment, data collection and genotyping. A logistic regression model which included gene-exposure interactions was applied. Likelihood ratio tests (LRTs) were used for significance testing and Bayesian inference was used to estimate odds ratios (ORs). MAPT (P = 0.007), SNCA REP1 (P = 0.012), smoking (P = 0.001), and coffee (P = 0.011) were associated with PD risk. Two novel interactions were detected: APOE with coffee (P = 0.005), and REP1 with smoking (P = 0.021). While the individual main effects were modest, each yielding OR < 1.6, the effects were cumulative, with some combinations reaching OR = 12.6 (95% CI: 5.9-26.8). This study provides evidence for the long-held notion that PD risk is modulated by cumulative and interactive effects of genes and exposures. Furthermore, the study demonstrates that while interaction studies are useful for exploring risk relationships that might otherwise go undetected, results should be interpreted with caution because of the inherent loss of power due to multiple testing. The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk.
authors.affiliation: Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA.
authors.forename: Colin C
authors.initials: CC
authors.lastname: McCulloch
authors.forename: Denise M
authors.initials: DM
authors.lastname: Kay
authors.forename: Stewart A
authors.initials: SA
authors.lastname: Factor
authors.forename: Ali
authors.initials: A
authors.lastname: Samii
authors.forename: John G
authors.initials: JG
authors.lastname: Nutt
authors.forename: Donald S
authors.initials: DS
authors.lastname: Higgins
authors.forename: Alida
authors.initials: A
authors.lastname: Griffith
authors.forename: John W
authors.initials: JW
authors.lastname: Roberts
authors.forename: Berta C
authors.initials: BC
authors.lastname: Leis
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Montimurro
authors.forename: Cyrus P
authors.initials: CP
authors.lastname: Zabetian
authors.forename: Haydeh
authors.initials: H
authors.lastname: Payami
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001057:Apolipoproteins E / Q000235:genetics*; D016022:Case-Control Studies; D004777:Environment; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000453:epidemiology / Q000235:genetics*; D011110:Polymorphism, Genetic; D012307:Risk Factors; D011795:Surveys and Questionnaires; D043222:Ubiquitin Thiolesterase / Q000235:genetics*; D051844:alpha-Synuclein / Q000235:genetics*; D016875:tau Proteins / Q000235:genetics*
chemical_list: D001057:Apolipoproteins E; C054369:MAPT protein, human; C497604:SNCA protein, human; C482860:UCHL1 protein, human; D051844:alpha-Synuclein; D016875:tau Proteins; D043222:Ubiquitin Thiolesterase